SAVA Stock Summary and Trading Ideas (Cassava Sciences | NASDAQ:SAVA)

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Cassava Sciences trades on the NASDAQ stock market under the symbol SAVA.

As of February 13, 2026, SAVA stock price climbed to $2.09 with 457,428 million shares trading.

SAVA has a beta of 1.54, meaning it tends to be more sensitive to market movements. SAVA has a correlation of 0.08 to the broad based SPY ETF.

SAVA has a market cap of $100.96 million. This is considered a Micro Cap stock.

In the last 3 years, SAVA traded as high as $42.20 and as low as $1.15.

The top ETF exchange traded funds that SAVA belongs to (by Net Assets): VTI, VXF, VHT, IWC, DFAS.

SAVA has underperformed the market in the last year with a return of -12.2%, while the SPY ETF gained +13.0%. In the last 3 month period, SAVA fell short of the market, returning -28.9%, while SPY returned +1.7%. However, in the most recent 2 weeks SAVA has outperformed the stock market by returning +5.0%, while SPY returned -1.5%.

SAVA support price is $1.96 and resistance is $2.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SAVA shares will trade within this expected range on the day.